Cara Therapeutics Stock News

Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean Worst Itching Intensity NRS score vs. placebo.

Regulatory News:

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 20) Abbott Laboratories (NYSE...

The "Postoperative Nausea & Vomiting (PONV) 2017-2028: Market Insights, Epidemiology and Forecast" drug pipelines has been added to ResearchAndMarkets.com's offering.

Alliancebernstein L.P. lifted its stake in shares of Cara Therapeutics Inc (NASDAQ:CARA) by 4.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchan

Bank of New York Mellon Corp decreased its stake in shares of Cara Therapeutics Inc (NASDAQ:CARA) by 10.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchan

Zacks Investment Research downgraded shares of Cara Therapeutics (NASDAQ:CARA) from a buy rating to a hold rating in a report published on Wednesday, Zacks.com reports. According to Zacks, “Cara The

Cara Therapeutics (NASDAQ:CARA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Tuesday, Zacks.com reports. The firm presently has a $1

Baldwin Brothers Inc. MA reduced its stake in Cara Therapeutics Inc (NASDAQ:CARA) by 23.8% during the first quarter, HoldingsChannel.com reports. The firm owned 17,027 shares of the biopharmaceutical

Needham analyst Alan Carr maintained a Buy rating on Cara Therapeutics (CARA) today and set a price target of $35.00. The company's shares closed last

Needham analyst Alan Carr maintained a Buy rating on Cara Therapeutics (CARA – Research Report) today and set a price

UBS Asset Management Americas Inc. raised its stake in shares of Cara Therapeutics Inc (NASDAQ:CARA) by 5.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned

Ladenburg Thalmann Financial Services Inc. lessened its position in shares of Cara Therapeutics Inc (NASDAQ:CARA) by 30.7% during the 4th quarter, according to its most recent Form 13F filing with the

299 cannabis companies have securities that actively trade on the various stock exchanges in Canada & the U.S.within 11 categories based on their primary area of focus.

AQR Capital Management LLC lowered its stake in Cara Therapeutics Inc (NASDAQ:CARA) by 5.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchang